Advertisement A Bayesian Design for a Seamless Transition Between Phase II and III - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

More info about
September 22, 2014

A Bayesian Design for a Seamless Transition Between Phase II and III

CASE STUDIES
By

Data collected by a sponsor suggested a possibility of a differential treatment in subpopulations defined by levels of a biomarker.

DOWNLOAD SPECIFICATIONS BROCHURE
Quick Contact


Top Products from

View all Products & Services